Measles, Mumps, Rubella Vaccine Market Size, Share, and Trends 2024 to 2034

The global measles, mumps, rubella vaccine market size is evaluated at USD 2.02 billion in 2025 and is forecasted to hit around USD 4.21 billion by 2034, growing at a CAGR of 8.51% from 2025 to 2034. The North America market size was accounted at USD 762.60 million in 2024 and is expanding at a CAGR of 8.64% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.

  • Last Updated : May 2025
  • Report Code : 6053
  • Category : Healthcare

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Measles, Mumps, Rubella Vaccine Market 

5.1. COVID-19 Landscape: Measles, Mumps, Rubella Vaccine Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Measles, Mumps, Rubella Vaccine Market, By Type

8.1. Measles, Mumps, Rubella Vaccine Market Revenue and Volume, by Type

8.1.1 Monovalent

8.1.1.1. Market Revenue and Volume Forecast

8.1.2. Trivalent (combined MMR)

8.1.2.1. Market Revenue and Volume Forecast

8.1.3. Tetravalent

8.1.3.1. Market Revenue and Volume Forecast

Chapter 9. Global Measles, Mumps, Rubella Vaccine Market, By Targeted Population

9.1. Measles, Mumps, Rubella Vaccine Market Revenue and Volume, by Targeted Population

9.1.1. Infants and Children (9 to 12 months)

9.1.1.1. Market Revenue and Volume Forecast

9.1.2. Adults

9.1.2.1. Market Revenue and Volume Forecast

Chapter 10. Global Measles, Mumps, Rubella Vaccine Market, By Distribution Channel

10.1. Measles, Mumps, Rubella Vaccine Market Revenue and Volume, by Distribution Channel

10.1.1. Hospitals and Healthcare Institutions

10.1.1.1. Market Revenue and Volume Forecast

10.1.2. Vaccine Centers and Public Health Clinics

10.1.2.1. Market Revenue and Volume Forecast

10.1.3. Pediatric and Private Healthcare Clinics

10.1.3.1. Market Revenue and Volume Forecast

Chapter 11. Global Measles, Mumps, Rubella Vaccine Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Volume Forecast, by Type

11.1.2. Market Revenue and Volume Forecast, by Targeted Population

11.1.3. Market Revenue and Volume Forecast, by Distribution Channel

11.1.4. U.S.

11.1.4.1. Market Revenue and Volume Forecast, by Type

11.1.4.2. Market Revenue and Volume Forecast, by Targeted Population

11.1.4.3. Market Revenue and Volume Forecast, by Distribution Channel

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Volume Forecast, by Type

11.1.5.2. Market Revenue and Volume Forecast, by Targeted Population

11.1.5.3. Market Revenue and Volume Forecast, by Distribution Channel

11.2. Europe

11.2.1. Market Revenue and Volume Forecast, by Type

11.2.2. Market Revenue and Volume Forecast, by Targeted Population

11.2.3. Market Revenue and Volume Forecast, by Distribution Channel

11.2.4. UK

11.2.4.1. Market Revenue and Volume Forecast, by Type

11.2.4.2. Market Revenue and Volume Forecast, by Targeted Population

11.2.4.3. Market Revenue and Volume Forecast, by Distribution Channel

11.2.5. Germany

11.2.5.1. Market Revenue and Volume Forecast, by Type

11.2.5.2. Market Revenue and Volume Forecast, by Targeted Population

11.2.5.3. Market Revenue and Volume Forecast, by Distribution Channel

11.2.6. France

11.2.6.1. Market Revenue and Volume Forecast, by Type

11.2.6.2. Market Revenue and Volume Forecast, by Targeted Population

11.2.6.3. Market Revenue and Volume Forecast, by Distribution Channel

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Volume Forecast, by Type

11.2.7.2. Market Revenue and Volume Forecast, by Targeted Population

11.2.7.3. Market Revenue and Volume Forecast, by Distribution Channel

11.3. APAC

11.3.1. Market Revenue and Volume Forecast, by Type

11.3.2. Market Revenue and Volume Forecast, by Targeted Population

11.3.3. Market Revenue and Volume Forecast, by Distribution Channel

11.3.4. India

11.3.4.1. Market Revenue and Volume Forecast, by Type

11.3.4.2. Market Revenue and Volume Forecast, by Targeted Population

11.3.4.3. Market Revenue and Volume Forecast, by Distribution Channel

11.3.5. China

11.3.5.1. Market Revenue and Volume Forecast, by Type

11.3.5.2. Market Revenue and Volume Forecast, by Targeted Population

11.3.5.3. Market Revenue and Volume Forecast, by Distribution Channel

11.3.6. Japan

11.3.6.1. Market Revenue and Volume Forecast, by Type

11.3.6.2. Market Revenue and Volume Forecast, by Targeted Population

11.3.6.3. Market Revenue and Volume Forecast, by Distribution Channel

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Volume Forecast, by Type

11.3.7.2. Market Revenue and Volume Forecast, by Targeted Population

11.3.7.3. Market Revenue and Volume Forecast, by Distribution Channel

11.4. MEA

11.4.1. Market Revenue and Volume Forecast, by Type

11.4.2. Market Revenue and Volume Forecast, by Targeted Population

11.4.3. Market Revenue and Volume Forecast, by Distribution Channel

11.4.4. GCC

11.4.4.1. Market Revenue and Volume Forecast, by Type

11.4.4.2. Market Revenue and Volume Forecast, by Targeted Population

11.4.4.3. Market Revenue and Volume Forecast, by Distribution Channel

11.4.5. North Africa

11.4.5.1. Market Revenue and Volume Forecast, by Type

11.4.5.2. Market Revenue and Volume Forecast, by Targeted Population

11.4.5.3. Market Revenue and Volume Forecast, by Distribution Channel

11.4.6. South Africa

11.4.6.1. Market Revenue and Volume Forecast, by Type

11.4.6.2. Market Revenue and Volume Forecast, by Targeted Population

11.4.6.3. Market Revenue and Volume Forecast, by Distribution Channel

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Volume Forecast, by Type

11.4.7.2. Market Revenue and Volume Forecast, by Targeted Population

11.4.7.3. Market Revenue and Volume Forecast, by Distribution Channel

11.5. Latin America

11.5.1. Market Revenue and Volume Forecast, by Type

11.5.2. Market Revenue and Volume Forecast, by Targeted Population

11.5.3. Market Revenue and Volume Forecast, by Distribution Channel

11.5.4. Brazil

11.5.4.1. Market Revenue and Volume Forecast, by Type

11.5.4.2. Market Revenue and Volume Forecast, by Targeted Population

11.5.4.3. Market Revenue and Volume Forecast, by Distribution Channel

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Volume Forecast, by Type

11.5.5.2. Market Revenue and Volume Forecast, by Targeted Population

11.5.5.3. Market Revenue and Volume Forecast, by Distribution Channel

Chapter 12. Company Profiles

12.1. Merck & Co., Inc.

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. GSK

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. Serum Institute of India Pvt. Ltd.

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. Sanofi

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. Shanghai Institute of Biological Products

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. Beijing Institute of Biological Products

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. Biological E Ltd.

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. Sinovac

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. Abbott

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. Abbott

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms

For questions or customization requests, please reach out to us at sales@precedenceresearch.com

Frequently Asked Questions

The global measles, mumps, rubella vaccine market size is expected to grow from USD 1.86 billion in 2024 to USD 4.21 billion by 2034.

The measles, mumps, rubella vaccine market is anticipated to grow at a CAGR of 8.51% between 2025 and 2034.

The major players operating in the measles, mumps, rubella vaccine market are Merck & Co., Inc., GSK, Serum Institute of India Pvt. Ltd., Sanofi, Shanghai Institute of Biological Products, Beijing Institute of Biological Products, Biological E Ltd., Sinovac, and Others.

The driving factors of the measles, mumps, rubella vaccine market are the increase the awareness about benefits of vaccination in communities across the world is likely to boost the growth of the market during the forecast period.

North America region will lead the global measles, mumps, rubella vaccine market during the forecast period 2025 to 2034.

Ask For Sample

No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client